Zoetis (ZTS) Return on Capital Employed (2013 - 2026)
Zoetis (ZTS) posted quarterly Return on Capital Employed of 27.36% for Q1 2026, down 507.0% year-over-year from 6.72% in Q1 2025, and down 1.18% quarter-over-quarter from 27.69% in Q4 2025.
Zoetis (ZTS) Return on Capital Employed (2013 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Return on Capital Employed for 14 consecutive years, with 27.36% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 507.0% year-over-year to 27.36%; the TTM figure through Mar 2026 stood at 27.36% (down 507.0% YoY), while the FY2025 annual figure was 29.01%, down 312.0% from the prior year.
- Return on Capital Employed slipped to 27.36% in Q1 2026 per ZTS's latest filing, from 27.69% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 32.8% in Q2 2025 and bottomed at 24.05% in Q1 2023.
- Historically, Return on Capital Employed has averaged 27.71% across 5 years, with a median of 27.36% in 2026.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 972 bps — and 2026, when it tumbled 507 bps.
- Zoetis' Return on Capital Employed stood at 27.59% in 2022, then dropped by 7 bps to 25.72% in 2023, then climbed by 25 bps to 32.03% in 2024, then slipped by 14 bps to 27.69% in 2025, then fell by 1 bps to 27.36% in 2026.
- Business Quant data shows ZTS's Return on Capital Employed at 27.36% in Q1 2026, 27.69% in Q4 2025, and 27.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 3.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.48% |
| Mar 31, 2026 | 27.36% |
| Dec 31, 2025 | 27.69% |
| Sep 30, 2025 | 27.64% |
| Jun 30, 2025 | 32.80% |
| Mar 31, 2025 | 32.42% |
| Dec 31, 2024 | 32.03% |
| Sep 30, 2024 | 27.24% |
| Jun 30, 2024 | 26.41% |
| Mar 31, 2024 | 26.23% |
| Dec 31, 2023 | 25.72% |
| Sep 30, 2023 | 25.61% |
| Jun 30, 2023 | 25.78% |
| Mar 31, 2023 | 24.05% |
| Dec 31, 2022 | 27.59% |
| Sep 30, 2022 | 27.45% |
| Jun 30, 2022 | 27.69% |
| Mar 31, 2022 | 27.32% |
| Dec 31, 2021 | 22.02% |
| Sep 30, 2021 | 20.63% |